Articles On Paradigm Biopharmaceuticals (ASX:PAR)

The past fortnight has seen another interesting list of buyers and sellers. Angel Seafood (ASX:AS1) CEO Issac Lee Halman had to sell $195,000 in shares to pay a tax bill. The company said he had no other choice because the majority of his a...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Participating in small cap raises is proving lucrative for investors, with shares in 47 small caps that tapped equity markets in April currently trading higher than the price at which they raised cash. Stockhead counted at least 66 offers i...

The company recently reported a 45% reduction in pain across 34 patients with knee osteoarthritis (OA) using its phase 3 clinical trial product Zilosul.

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

Special Report: Drug developer Dimerix hasn’t been affected by the March market rout and since April has surged. What is behind this push? Shares in drug developer Dimerix (ASX:DXB) have doubled in value in the last six months and the stock...

It’s still a relatively difficult market to raise capital in, particularly at the junior end, but there are some that have convinced investors to part with their hard earned cash. We run through just which small and micro caps successfully...

Paradigm Biopharmaceuticals (ASX: PAR) has completed treatment of its Zilosul injectable pentosan polysulfate (iPPS) drug under the US Food and Drug Administration’s expanded access program, while collaring FDA orphan status for using it in...

Earlier this month, Paradigm reported a 45% mean reduction in pain score across 34 patients with knee osteoarthritis (OA) using Zilosul.

The Paradigm Biopharmaceuticals Limited (ASX: PAR) share price is up 9.03% at the time of writing after the healthcare company reported strong results from its clinical studies. Paradigm’s drug Zilosul reportedly reduced chronic pain in os...

We know that gambling dens aren’t open in these days of social distancing, but metaphorically speaking Paradigm Pharmaceuticals (ASX:PAR) is plonking it all on the black in terms of its “ballsy” pursuit of US approval for its drug for osteo...

The recent market announcements and $35 million capital raise have provided significant clarity to numerous aspects of the company’s development pathway for Zilusol.

The company aims to develop and commercialise its safe and effective treatment for sufferers of osteoarthritis.

Zilosul was successful in reducing knee osteoarthritis pain score by 45%.

Drug company Paradigm Biopharmaceuticals has had Bell Potter line up investors for a $35 million equity raising.

The halt will remain in place until Monday, April 6, or until an announcement is released to the market.

Humanity is against a race with time, as the pandemic coronavirus is accelerating. According to the WHO, the number of confirmed cases across the globe has exceeded 3,81,598, while the number of deaths has surpassed 16,000 (as on 24 March 2...

The S&P/ASX 200 Index (ASX: XJO) has returned to form on Tuesday. In late morning trade the benchmark index is up a decent 2.3% to 4,650.5 points. Four shares that are climbing more than most today are listed below. Here’s why they are...

10 Patients are being treated for knee osteoarthritis using the trademarked injectable pentosan polysulphate sodium drug Zilosul®.

An experimental treatment for knee osteoarthritis developed by Paradigm Biopharmaceuticals (ASX: PAR), Zilosul, has now been dosed in all ten patients under the FDA approved expanded access – otherwise known as compassionate use – program i...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is charging higher on Tuesday morning. At the time of writing the biopharmaceutical company’s shares are up 17% to $1.41. Why is the Paradigm share price charging higher? Investors...

The ASX healthcare sector continues to be one of the top performers on the ASX in terms of share price rises over the past 12 months, despite all the strong market correction. While most Australians are likely familiar with healthcare comp...

Over the last 12 months there have been some outstanding performers on the Australian share market. Some shares have beaten the market with solid gains and others have absolutely smashed it with mouth-watering gains. Here’s why these All O...

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is an Australian biopharmaceutical company, which focuses on repurposing pentosan polysulfate sodium (PPS) for the treatment of medical conditions and diseases. Paradigm’s share price has tripled...

The biotechnology company is undergoing regulatory processes in Australia, the US and Europe for its injectable Pentosan Polysulfate Sodium (iPPS) drug.

The company is focused on repurposing the injectable drug pentosan polysulphate sodium to treat inflammation in MPS VI patients.

Growing ASX-listed biotech company Paradigm Biopharmaceuticals Ltd (ASX: PAR) has performed strongly over the last year, with Paradigm shares skyrocketing more than 250% higher to $4.20 as at the time of writing. This means it has outperf...

The Opthea Ltd (ASX: OPT) share price has already surged over 20% higher in January to $3.60 as at the time of writing. Although the 52-week high of $4.15 the biotechnology company hit back in September still seems like a little way off ye...

With the market in fine form so far this year, it will come as no surprise to learn that a number of shares have just hit 52-week highs or better. Three shares that have just reached this milestone are listed below. Here’s why they are sca...

I’m a big fan of investing in the mid cap side of the market. This is because it generally offers greater potential returns that the large cap space, but comes with less risk than the small cap side of the market. Three mid cap ASX shares...

I’m sure that many readers have aspirations to become a millionaire one day. And while a lucky few may achieve this through buying a lottery ticket on the Jumbo Interactive Ltd (ASX: JIN) operated Oz Lotteries website, the odds are certain...

I think that one of the best ways to make market-beating returns is to have a little exposure to the small cap side of the market. After all, it wasn’t that long ago that Altium Limited (ASX: ALU) and Appen Ltd (ASX: APX) were classed as s...

Due to a number of positive trends such as increased chronic disease burden and ageing populations, I believe the healthcare sector is one of the best places to invest your money with a long term view. With that in mind, here are three ver...

Over the last 12 months the Opthea Ltd (ASX: OPT) share price has been one of the best performers on the All Ordinaries index. During this time the shares of the developer of novel biologic therapies for the treatment of eye diseases have...

It was a great year for ASX healthcare shares in 2019, with the S&P/ASX Healthcare Index increasing by 41%. These 3 ASX healthcare shares experienced even greater gains in 2019, but can they continue to outperform in 2020?  Avita Med...

If your portfolio doesn’t have exposure to the small side of the market, I think it would be well worth considering adding one or two small cap shares to it if your risk profile allows. After all, you only need to look at Altium Limited (A...

There are more than 150 healthcare shares listed on the ASX, varying from pharmaceutical manufacturers, to medical software developers to facility operators. So where should you start if you want to add ASX healthcare shares to your portfo...

The S&P/ASX 200 index is ending the year with a day in the red. In afternoon trade the benchmark index is down a sizeable 1.7% to 6,688.7 points. Four shares that have not let that hold them back today are listed below. Here’s why they...

A new year is upon us, so what better time to look at potential new additions to your portfolio. If you’re interested in gaining a little exposure to the small side of the market, then the three ASX shares listed below could be the ones to...

Due to populations around the world getting older and chronic disease burden increasing, demand for healthcare services continues to rise. I believe this trend will continue for several decades, which could make the healthcare sector a gre...

On Christmas Day I picked out 10 top ASX shares that I think could be great options for investors in 2020. But they weren’t the only shares that I would be buying right now. Here are 10 more top ASX shares to own in 2020: Nearmap Ltd (ASX:...

In late trade S&P/ASX 200 index is having a subdued end to the day ahead of the Christmas break. At the time of writing the benchmark index is flat at 6,786.7 points. Four shares that are out of form on Tuesday are listed below. Here’s...

I think the Australian share market is home to a large number of small cap shares that have the potential to grow materially larger in the future. While history shows that not all small caps deliver on their potential, I think many of thes...

In afternoon trade the S&P/ASX 200 index has come under pressure and is trading notably lower. At the time of writing the benchmark index is down 0.75% to 6,701.9 points. Four shares that have fallen more than most today are listed bel...

With progress to secure regulatory approvals underway for its flagship Zilosul treatment Paradigm Biopharmaceuticals (ASX: PAR) is also gearing up for phase 2/3 clinical trial in the first quarter of next year. Paradigm is preparing for a j...

In morning trade the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is sinking lower despite the release of its end of year update. At the time of writing the biopharmaceutical company’s shares are down 4% to $3.00. What was in Par...

Paradigm will be meeting with the US FDA in Feb 2020 for a pre-IND meeting among other things.

The S&P/ASX 200 index has returned to form and is pushing higher this afternoon. At the time of writing the benchmark index is up 0.4% to 6,732.4 points. Four shares that have failed to follow the market higher today are listed below....

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are up from 99 cents on New Year’s day 2019 to $3.49 today and even hit as high as $4.12 last November. What does Paradigm do? With its shares up 250% in less than a year you’d think Paradi...

The S&P/ASX 200 index has followed the lead of U.S. markets and is dropping lower today. At the time of writing the benchmark index is down 0.15% to 6,719.8 points. Four shares that have fallen more than most today are listed below. He...